Results 221 to 230 of about 2,022,996 (246)
Some of the next articles are maybe not open access.
Anticancer Research
Colorectal cancer (CRC) is a leading cause of cancer-related deaths, often due to liver metastases. Neoantigen-based immunotherapy has shown promise in clinical trials of solid tumors, including CRC. However, the immunogenic factors of neoantigens and their optimal selection in metastatic tumors are not well understood.
Xiaolin, Yu +9 more
openaire +2 more sources
Colorectal cancer (CRC) is a leading cause of cancer-related deaths, often due to liver metastases. Neoantigen-based immunotherapy has shown promise in clinical trials of solid tumors, including CRC. However, the immunogenic factors of neoantigens and their optimal selection in metastatic tumors are not well understood.
Xiaolin, Yu +9 more
openaire +2 more sources
Cancer Research, 2020
Abstract Background: Biallelic inactivation of CDK12 is associated with a distinct genomic signature of focal tandem duplications (FTDs). Gene fusions resulting from CDK12-associated FTDs increase neoantigen load, raising interest in CDK12 as a biomarker of response to immune checkpoint inhibitors (ICIs). Although FTDs have been detected
Andrew Elliott +10 more
openaire +1 more source
Abstract Background: Biallelic inactivation of CDK12 is associated with a distinct genomic signature of focal tandem duplications (FTDs). Gene fusions resulting from CDK12-associated FTDs increase neoantigen load, raising interest in CDK12 as a biomarker of response to immune checkpoint inhibitors (ICIs). Although FTDs have been detected
Andrew Elliott +10 more
openaire +1 more source
Cancer Research, 2020
Abstract Checkpoint inhibitor therapy has demonstrated meaningful, if varied antitumor activity, with patient response influenced by a variety of biological factors, including complex interactions between the tumor and immune system.
Charles W. Abbott +6 more
openaire +1 more source
Abstract Checkpoint inhibitor therapy has demonstrated meaningful, if varied antitumor activity, with patient response influenced by a variety of biological factors, including complex interactions between the tumor and immune system.
Charles W. Abbott +6 more
openaire +1 more source
Cancer Research, 2017
Abstract Introduction: The recent clinical demonstrations that cancer immunotherapy is effective for some patients, but not others has led to widespread interest in identifying cancer genetic factors that can predict positive response.
Alex So +6 more
openaire +1 more source
Abstract Introduction: The recent clinical demonstrations that cancer immunotherapy is effective for some patients, but not others has led to widespread interest in identifying cancer genetic factors that can predict positive response.
Alex So +6 more
openaire +1 more source
Cancer Research, 2018
Abstract Despite the remarkable response of some melanoma patients to checkpoint inhibitor therapy, significant numbers of patients do not achieve complete response. To understand this differential response, there is an increasing interest in identifying biomarkers and mechanisms that influence immunotherapy effectiveness. In this study,
Jie Wang +6 more
openaire +1 more source
Abstract Despite the remarkable response of some melanoma patients to checkpoint inhibitor therapy, significant numbers of patients do not achieve complete response. To understand this differential response, there is an increasing interest in identifying biomarkers and mechanisms that influence immunotherapy effectiveness. In this study,
Jie Wang +6 more
openaire +1 more source
Journal of Clinical Oncology
e16003 Background: Hepatocellular Carcinoma (HCC) patients has a high postoperative recurrence within 2 years and a low 5-year survival rate. However, molecular mechanisms for early recurrence are poorly understood. Immune checkpoint blockades (ICBs) show clinical benefits in HCC, with the immune microenvironment influencing ICBs therapeutic effects.
Wenting Liao, Yue Xiao, Wei Guo
openaire +1 more source
e16003 Background: Hepatocellular Carcinoma (HCC) patients has a high postoperative recurrence within 2 years and a low 5-year survival rate. However, molecular mechanisms for early recurrence are poorly understood. Immune checkpoint blockades (ICBs) show clinical benefits in HCC, with the immune microenvironment influencing ICBs therapeutic effects.
Wenting Liao, Yue Xiao, Wei Guo
openaire +1 more source
Brain and Other Central Nervous System Tumor Statistics, 2021
Ca-A Cancer Journal for Clinicians, 2021Rebecca L. Siegel +2 more
exaly
Method and system for calculating tumor neoantigen burden
2022WAN JI +5 more
openaire +2 more sources
Clinical Utility of Solid Tumor Epigenetics
Medical Epigenetics, 2021Sevin Turcan, Julian Taranda
exaly
Circulating Tumor DNA in Advanced Solid Tumors: Clinical Relevance and Future Directions
Ca-A Cancer Journal for Clinicians, 2021Heather Parsons +2 more
exaly